Compare Adaptive Biotechnologies Corp (ADPT) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Jumia Technologies AG - ADR — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while Jumia Technologies AG - ADR trades at $6.45 (market cap $719.58M). The key difference: Adaptive Biotechnologies Corp is far larger — about 5.6× Jumia Technologies AG - ADR's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals.
| ADPT | JMIA | |
|---|---|---|
Market Cap | $4.04B | $719.58M |
Sector | Health | Consumer Cyclical |
52-Week High | $25.45 | $14.60 |
52-Week Low | $12.30 | $5.69 |
Enterprise Value | $4.10B | $666.68M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
JMIA trades at $6.325, up 5.42% today, but technical indicators show a bearish trend with moving averages signaling sell. The company reported a net loss of $61.55 million in 2025, though revenue grew to $188.93 million and the net loss margin improved to -32.58%. Recent news highlights progress toward Q4 2026 breakeven and a $50 million capital raise.
The outlook remains speculative with persistent losses and high valuation ratios like P/B of 55.05, but analyst consensus is bullish with 71% buy ratings. Key risks include cash burn and competitive pressures, while catalysts include continued operating leverage and expansion initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
